Modulation of metabolism and cytotoxicity of cytosine arabinoside with N-(phosphon)-acetyl-L-aspartate in human leukemic blast cells and cell lines

Leukemia Research

Volumn 20, Issue 2, 1996, Pages 127-134

  Noordhuis, Paul ^a   Kazemier, Karin M ^a   Kaspers, Gert Jan L ^a   Peters, Godefridus J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Accumulation; Cytosine arabinoside; Cytotoxicity; Incorporation; N (phosphon) acetyl L aspartate; Nucleotides

Indexed keywords

CYTARABINE; CYTARABINE TRIPHOSPHATE; CYTIDINE TRIPHOSPHATE; DEOXYCYTIDINE TRIPHOSPHATE; PYRIMIDINE NUCLEOTIDE; SPARFOSIC ACID; URIDINE TRIPHOSPHATE;

ARTICLE; BLAST CELL; CELL STRAIN HL 60; CYTOTOXICITY; DRUG DNA INTERACTION; DRUG METABOLISM; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; METABOLIC ACTIVATION; PRIORITY JOURNAL;

EID: 0029967727     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/0145-2126(95)00071-2     Document Type: Article

References (32)

1. Grant S. (1990) Biochemical modulation of cytosine arabinoside. Pharmac. Ther. 48, 29.
2. Ross D. D., Serena Chen R.-S. & Cuddy D. P. (1990) Effects of 1-β-D arabinofuranosylcytosine on DNA replication intermediates monitored by pH-step alkaline elution. Cancer Res. 50, 2658.
3. Ruiz van Haperen V. W. T. & Peters G. J. (1994) New targets for pyrimidine antimetabolites for the treatment of solid tumors 2: Deoxycytidine kinase. Pharmacy World and Science 16, 104.
4. Plunkett W. & Gandhi V. (1993) Cellular pharmacodynamics of anti-cancer drugs. Semin. Oncol. 20, 50.
5. Rustum Y. M. & Raymakers R. A. P. (1992) 1-β-D-Arabinofuranosylcytosine in therapy of leukaemia - pre-clinical and clinical overview. Pharmacol. Ther. 56, 307.
6. Momparler R. L. & Onetto-Pothier N. (1989) Drug resistance to cytosine arabinoside. In Resistance to Antineoplastic Drugs (Kessel D, Ed.), pp. 353-367. CRC Press, Boca Raton.
7. White J. C. & Hines L. H. (1987) Role of uridine triphosphate in the phosphorylation of 1-β-D-arabinofuranosylcytosine by Ehrlich ascites tumor cells. Cancer Res. 47, 1820.
8. White J. C. & Capizzi R. L. (1991) A critical role for uridine nucleotides in the regulation of deoxycytidine kinase and the concentration dependence of 1-β-D-arabinofuranosylcytosine phosphorylation in human leukemic cells. Cancer Res. 51, 2559.
9. Shewach D. S., Reynolds K. K. & Hertel L. W. (1992) Nucleotide specificity of human deoxycytidine kinase. Mol. Pharmacol. 42, 518.
10. Peters G. J. & Van Groeningen C. J. (1991) Clinical relevance of biochemical modulation of 5-fluorouracil. Ann. Oncol. 2, 469.
11. Martin D. S. (1987) Biochemical modulation: perspectives and objectives. In: Proceedings of the 8th Bristol-Meyers Symposium on Cancer Research. New Avenues in Developmental Cancer Chemotherapy (Harrap K. R. & Connors T. A., Eds), pp. 113-162. Academic Press, London.
12. Rustum Y. M., Danhauser L., Luccioni C. & Au J. L. S. (1981) Determinants of response to antimetabolites by purine and pyrimidine metabolites. Cancer Treat. Rep. 65, 73.
13. Rustum Y. M. (1991) Modulation of fluoropyrimidines by leucovorin: rationale and status. J. Surg. Oncol. Suppl 2, 116.
14. Grant S., Rauscher III F. & Cadman E. (1982) Differential effect of N-(phosphonacetyl)-L-aspartate on 1-β-D-arabinofuranosylcytosine metabolism and cytotoxicity in human leukemia and normal bone marrow progenitors. Cancer Res. 42, 4007.
15. Grant S., Bhalla K. & Gleyzer M. (1984) Effect of uridine on response of 5-azacytidine-resistant human leukemic cells to inhibitors of de novo pyrimidine synthesis. Cancer Res. 44, 5505.
16. Blumenreich M., Andreef M., Chou T. C., Wittes R., Clarkson B. & Young C. (1981) Kinetic and biochemical modulation of pyrimidine anti-metabolites in therapy of acute leukemia. Proc. Am. Assoc. Cancer Res. 22, 193 (Abstract).
17. Plunkett W., Adams T. & Keating M. (1987) Modulation of Ara-CTP metabolism in leukemia cells during high-dose Ara-C (HD Ara-C) therapy by thymidine and PALA. Proc. Am. Assoc. Clin. Oncol. 6, 30 (Abstract).
18. Plunkett W., Liliemark J. O., Adams T. M., Nowak B., Estey E., Kantarjian H. & Keating M. J. (1987) Saturation of 1-β-D-arabinofuranosylcytosine-5′-triphosphate accumulation in leukemia cells during high-dose 1-β-D-arabinofuranosylcytosine therapy. Cancer Res. 47, 3005.
19. Alley M. C., Scudiero D. A., Monks A., Hursey M. L., Czerwinski M. J., Fine D. L., Abbott B. J., Mayo J. G., Shoemaker R. H. & Boyd M. R. (1988) Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 48, 589.
20. Keepers Y. P., Pizao P. E., Peters G. J., Van Ark-Otte J., Winograd B. & Pinedo H. M. (1991) Comparison of the sulforhodamine B protein and the tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur. J. Cancer 27, 897.
21. Peters G. J., Wets M., Keepers Y. P. A. M., Oskam R., Van Ark-Otte J., Noordhuis P., Smid K. & Pinedo H. M. (1993) Transformation of mouse fibroblasts with the oncogenes H-ras or trk is associated with pronounced changes in drug sensitivity and metabolism. Int. J. Cancer 54, 450.
22. Boyd M. R., Paull K. D. & Rubinstein L. (1992) Data display and analysis strategies for the NCI disease-oriented in vitro drug screen. In Cytotoxic Anticancer Drug: Models and Concepts for Drug Discovery and Development (Valeriote F. A., Corbett T. H., Baker L. H., Eds), pp. 11-34. Kluwer, Boston.
23. Kaspers G. J. L., Pieters R., Van Zantwijk C. H., De Laat P. A. J. M., De Waal F. C., Van Wering E. R. & Veerman A. J. P. (1991) In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood. Br. J. Cancer 64, 469.
24. Van der Doel L. J., Pieters R., Huismans D. R., Van Zantwijk C. H., Loonen A. H., Broekema G. J., De Waal F. C. & Veerman A. J. P. (1988) The immunological phenotype of lymphoid cells in regenerating bone marrow of children after treatment for acute lymphoblastic leukemia. Eur. J. Haematol. 41, 170.
25. Pieters R., Loonen A. H., Huismans D. R., Broekema G. J., Dirven M. W. J., Heyenbrok M. W., Hahlen K. & Veerman A. J. P. (1990) In vitro sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood 76, 2327.
26. Peters G. J., Laurensse E., Leyva A., Lankelma J. & Pinedo H. M. (1986) Sensitivity of human, murine and rat cells to 5-fluorouracil and 5′-deoxy-5-fluorouridine in relation to drug metabolizing enzymes. Cancer Res. 46, 20.
27. Van der Wilt C. L., Visser G. W. M., Braakhuis B. J. M., Wedzinga R., Noordhuis P., Smid K. & Peters G. J. (1993) In vitro antitumour activity of cis- and trans-5-fluoro-5,6-dihydro-6 alkoxy-uracils; effects on thymidylate synthesis. Br. J. Cancer. 38, 702.
28. Moore E. C. (1982) N-(phosphonacetyl)-L-aspartate inhibition of the enzyme complex of pyrimidine biosynthesis. Biochem. Pharmacol. 31, 3313.
29. Moore E. C. (1982) Aspartate carbamoyltransferase activity, drug concentrations, and pyrimidine nucleotides in tissue from patients treated with N-(phosphonacetyl)-L-aspartate. Biochem. Pharm. 31, 3317.
30. Martin D. S., Stolfi R. L., Sawyer R. C., Spiegelman S., Casper E. S. & Young C. W. (1983) Therapeutic utility of utilizing low doses of N-(phosphonacetyl)-L-aspartic acid in combination with 5-fluorouracil: a murine study with clinical relevance. Cancer Res. 43, 2317.
31. Van Laar J. A. M., Durrani F. A. & Rustum Y. M. (1993) Antitumor activity of the weekly intravenous push schedule of 5-fluoro-2′-deoxyuridine±N-phosphon-L-aspartate in mice bearing advanced colon carcinoma 26. Cancer Res. 53, 1560.
32. Grem J. L., King S. A., O'Dwyer P. J. & Leyland-Jones B. (1988) Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate: a review. Cancer Res. 48, 4441.